发明名称 |
Biomarkers and methods for determining efficacy of anti-EGFR antibodies in cancer therapy |
摘要 |
<p>The invention relates to biomarkers based on gene expression products and methods for determining the efficacy of anti-EGFR antibodies in the treatment of EGFR expressing cancer. The invention is further related to the prediction of sensitivity or resistance of a patient suffering from EGFR expressing cancer to the treatment of said patient with a specific anti- EGFR antibody. The invention is preferably related to the identification of respective biomarkers that allow a better prediction of the clinical outcome of the treatment with anti- EGFR antibodies in patients with KRAS wild-type tumors. In this context, the invention especially relates to anti-EFGR antibody c225/cetuximab (Erbitux®) and its use in patients suffering from colorectal Cancer (CRC).</p> |
申请公布号 |
AU2010262133(A1) |
申请公布日期 |
2012.02.02 |
申请号 |
AU20100262133 |
申请日期 |
2010.06.15 |
申请人 |
MERCK PATENT GMBH |
发明人 |
STROH, CHRISTOPHER;VON HEYDEBRECK, ANJA |
分类号 |
C12Q1/68;G01N33/574 |
主分类号 |
C12Q1/68 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|